MapLight Therapeutics, Inc. — Form 8-K
Filed November 16, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
MapLight Therapeutics reported positive Phase 2 ZEPHYR trial results for ML-007C-MA (210/3 mg BID) in schizophrenia, meeting its primary endpoint with PANSS total score reduction of 4.5 points vs. placebo (effect size 0.37, p=0.015; 0.50 in completers). The company raised $150M in August 2026 and ended Q3 2026 with $463.4M cash, sufficient to fund operations through 2028, including planned Phase 3 ZEPHYR-2 trial (topline 2H 2027) and ongoing Phase 2 VISTA trial in Alzheimer's disease psychosis (topline 2028). ML-007C-MA also showed prespecified cognitive benefit (effect size 0.51, p=0.041) and was well-tolerated with 99% reaching target dose and low GI discontinuations (2%), contrasting favorably with Cobenfy's safety profile.
Why this rating
Successful Phase 2 de-risks registrational path; $463M cash runway (125% of company size) funds pivotal trials; cognitive signal differentiates competitor landscape meaningfully.
Tradability signal
NO TRADE
No trade: positive news with no measurable pre-read move — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.43% over 4 hrs, n=488). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $7.14 | +10 min · unknown $7.14 ▲ 0.00% | +30 min · unknown $6.96 ▼ 2.45% | +1 hr · unknown $7.19 ▲ 0.70% | +4 hrs · unknown $6.94 ▼ 2.80% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.